Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial

被引：0
|
作者：
Peter Schmid
J. Krocker
R. Kreienberg
P. Klare
K. Kittel
H. Sommer
G. Heinrich
T. Steck
W. Lichtenegger
D. Elling
S. Kümmel
机构：
[1] Imperial College London,Department of Medical Oncology, Charing Cross Hospital
[2] Sana Hospital Lichtenberg,Department of Obstetrics and Gynecology
[3] University of Ulm,Department of Obstetrics and Gynecology
[4] Clinic for Gynaecological Oncology,Department of Obstetrics and Gynecology
[5] Ludwig Maximilians University Munich,Department of Obstetrics and Gynecology
[6] Clinic for Gynaecological Oncology,Department of Obstetrics and Gynecology
[7] Hospital Chemnitz,Department of Obstetrics and Gynecology
[8] Charité University Medical Center,undefined
[9] University Hospital Essen,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2009年 / 64卷
关键词：
Docetaxel; Non-pegylated liposomal doxorubicin; Cardiotoxicity; Metastatic breast cancer; Chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：401 / 406
页数：5
相关论文
共 50 条
  • [31] Weekly combination of non-pegylated liposomal doxorubicin and taxane in first-line breast cancer: wALT trial (phase I-II)
    Rosati, M. S.
    Raimondi, C.
    Baciarello, G.
    Grassi, P.
    Giovannoni, S.
    Petrelli, E.
    Basile, M. L.
    Girolami, M.
    Di Seri, M.
    Frati, L.
    ANNALS OF ONCOLOGY, 2011, 22 (02) : 315 - 320
  • [32] Comment on Pegylated Liposomal Doxorubicin Plus Docetaxel in Metastatic Breast Cancer Reply
    Sparano, Joseph A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (08) : E129 - E130
  • [33] Non-pegylated liposomal doxorubicin in older adjuvant early breast cancer patients: cardiac safety analysis and final results of the COLTONE study
    Luigi Coltelli
    Chiara Finale
    Gianna Musettini
    Andrea Fontana
    Maria Teresa Barletta
    Alessandra Renata Lucarini
    Iacopo Fabiani
    Marco Scalese
    Guido Bocci
    Luna Chiara Masini
    Giulia Soria
    Samanta Cupini
    Giada Arrighi
    Cecilia Barbara
    Ermelinda De Maio
    Barbara Salvadori
    Andrea Marini
    Antonio Pellino
    Irene Stasi
    Michele Emdin
    Stefano Giaconi
    Lorenzo Marcucci
    Giacomo Allegrini
    Clinical and Experimental Medicine, 2023, 23 : 5113 - 5120
  • [34] Non-pegylated liposomal doxorubicin in older adjuvant early breast cancer patients: cardiac safety analysis and final results of the COLTONE study
    Coltelli, Luigi
    Finale, Chiara
    Musettini, Gianna
    Fontana, Andrea
    Barletta, Maria Teresa
    Lucarini, Alessandra Renata
    Fabiani, Iacopo
    Scalese, Marco
    Bocci, Guido
    Masini, Luna Chiara
    Soria, Giulia
    Cupini, Samanta
    Arrighi, Giada
    Barbara, Cecilia
    De Maio, Ermelinda
    Salvadori, Barbara
    Marini, Andrea
    Pellino, Antonio
    Stasi, Irene
    Emdin, Michele
    Giaconi, Stefano
    Marcucci, Lorenzo
    Allegrini, Giacomo
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (08) : 5113 - 5120
  • [35] Neoadjuvant chemotherapy with non-pegylated liposomal doxorubicin, docetaxel and trastuzumab in HER-2/neu overexpressing breast cancer
    Schippinger, Walter
    Lileg, Brigitte
    Ploner, Ferdinand
    Weitzer, Werner
    Bauemhofer, Thomas
    Samonigg, Hellmut
    ANNALS OF ONCOLOGY, 2007, 18 : 166 - 166
  • [36] Phase II Study of Bortezomib and Pegylated Liposomal Doxorubicin in the Treatment of Metastatic Breast Cancer
    Irvin, William J., Jr.
    Orlowski, Robert Z.
    Chiu, Wing-Keung
    Carey, Lisa A.
    Collichio, Frances A.
    Bernard, Philip S.
    Stijleman, Inge J.
    Perou, Charles
    Ivanova, Anastasia
    Dees, E. Claire
    CLINICAL BREAST CANCER, 2010, 10 (06) : 465 - 470
  • [37] Phase II evaluation of liposomal doxorubicin combined with docetaxel in patients with metastatic breast cancer
    Fasano, J.
    Hershman, D.
    Novik, Y.
    Blozie, K.
    Tiersten, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [38] Pegylated liposomal doxorubicin in previously treated patients with metastatic breast cancer - a large multicenter phase II trial
    Al-Batran, SE
    Bischoff, J
    von Minckwitz, G
    Atmaca, A
    Kleeberg, U
    Meuthen, I
    Morack, G
    Lerbs, W
    Hccker, D
    Jager, E
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S280 - S280
  • [39] Weekly Non-pegylated Liposomal Doxorubicin Chemotherapy in Heavily Pre-treated Patients with Metastatic Breast Cancer
    Masci, Giovanna
    Gandini, Chiara
    Zuradelli, Monica
    Losurdo, Agnese
    Torrisi, Rosalba
    Rota, Selene
    Gullo, Giuseppe
    Velutti, Laura
    Giordano, Laura
    Santoro, Armando
    ANTICANCER RESEARCH, 2013, 33 (10) : 4603 - 4609
  • [40] A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
    Huober, Jens
    Fett, Werner
    Nusch, Arnd
    Neise, Michael
    Schmidt, Marcus
    Wischnik, Arthur
    Gerhardt, Steffen
    Goehler, Thomas
    Lueck, Hans-Joachim
    Rost, Andreas
    BMC CANCER, 2010, 10
12345